Lucid Diagnostics (LUCD) to Release Quarterly Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCD) is expected to issue its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Lucid Diagnostics to post earnings of ($0.06) per share and revenue of $1.3540 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:30 AM ET.

Lucid Diagnostics Stock Up 0.9%

NASDAQ:LUCD opened at $1.08 on Monday. The firm’s fifty day simple moving average is $1.15 and its 200-day simple moving average is $1.17. The stock has a market cap of $144.16 million, a PE ratio of -0.91 and a beta of 1.22. Lucid Diagnostics has a fifty-two week low of $0.75 and a fifty-two week high of $1.80.

Insider Activity

In other news, Director Dennis Matheis purchased 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director directly owned 665,443 shares in the company, valued at $678,751.86. This represents a 17.69% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Lucid Diagnostics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock valued at $4,569,000 after acquiring an additional 396,719 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Lucid Diagnostics in the second quarter valued at about $43,000. Invesco Ltd. acquired a new position in shares of Lucid Diagnostics during the second quarter worth about $41,000. New York State Common Retirement Fund purchased a new stake in shares of Lucid Diagnostics in the second quarter worth about $97,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after buying an additional 32,672 shares during the period. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LUCD shares. Ascendiant Capital Markets increased their target price on shares of Lucid Diagnostics from $7.75 to $8.00 and gave the company a “buy” rating in a report on Monday, October 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday. Wall Street Zen raised Lucid Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, October 14th. Needham & Company LLC reiterated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Wednesday, August 13th. Finally, BTIG Research raised their price target on Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research report on Friday, September 5th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.70.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.